Harvey Snyder, MD
Cardiovascular Disease · Haddon Heights, NJNPI 1003869488
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 435 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$915
- Impulse Dynamics (USA) Inc.$649
- E.r. Squibb & Sons, L.L.C.$345
- Johnson & Johnson$340
- Amgen$329
- plus $2K from 27 others
Across 70 payments — averaging $1234.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$29K
- AstraZeneca$27K
- Astrazeneca UK Limited$18K
- Merck$12K
What the payments were for
- Food & beverage$6,261100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 118 | $1,331 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 70 | $915 |
| Impulse Dynamics (USA) Inc. | 26 | $649 |
| E.r. Squibb & Sons, L.L.C. | 35 | $345 |
| Johnson & Johnson | 23 | $340 |
| Amgen | 23 | $329 |
| Pfizer | 22 | $327 |
| Abbott | 9 | $283 |
| Amarin Pharma, Inc. | 21 | $274 |
| AstraZeneca | 11 | $264 |
| Merck | 13 | $174 |
| Kowa Pharmaceuticals America, Inc. | 10 | $141 |
| Bayer | 6 | $108 |
| Atricure, Inc. | 3 | $87 |
| Regeneron Healthcare Solutions, Inc. | 5 | $81 |
| Novo Nordisk | 5 | $72 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| Boehringer Ingelheim | 5 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Boston Scientific | 2 | $53 |
| Edwards Lifesciences | 2 | $39 |
| W. L. Gore & Associates, Inc. | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $24 |
| Sanofi | 1 | $20 |
| GSK | 1 | $18 |
| Regeneron | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $13 |
How this compares
$6,277 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 241 | $338,873 |
| XareltoRivaroxaban | 71 | $93,511 |
| Repatha SureclickEvolocumab | 66 | $72,955 |
| EntrestoSacubitril/Valsartan | 37 | $46,269 |
| FarxigaDapagliflozin Propanediol | 19 | $24,845 |
| JardianceEmpagliflozin | 13 | $16,706 |
| VascepaIcosapent Ethyl | 28 | $12,626 |
| Praluent PenAlirocumab | 14 | $10,081 |
| Icosapent Ethyl | 18 | $9,949 |
| Atorvastatin Calcium | 869 | $9,868 |
| Metoprolol Succinate | 480 | $7,543 |
| Ezetimibe | 232 | $7,008 |
| Rosuvastatin Calcium | 362 | $6,999 |
| Losartan Potassium | 265 | $2,993 |
| Valsartan | 46 | $2,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $327 | $338,873241 claims |
| Johnson & JohnsonXarelto | $340 | $93,51171 claims |
| NovartisEntresto | $1,331 | $46,26937 claims |
| AstraZenecaFarxiga | $264 | $24,84519 claims |
| Boehringer IngelheimJardiance | $68 | $16,70613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Haddon Heights
- Dilip ViswanathHaddon Heights$167K
- Andreas PavlidesHaddon Heights$43K
- Vijayendra VermaHaddon Heights$32K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.